FindTrial
Sign In

Cytoreductive surgery with intraperitoneal hyperthermic perfusion chemotherapy clinical Study on treatment of peritoneal carcinoma and application

Cytoreductive surgery with intraperitoneal hyperthermic perfusion chemotherapy clinical Study on treatment of peritoneal carcinoma and application

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16009661
Enrollment
Unknown
Registered
2016-10-27
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peritoneal carcinoma

Interventions

Group A:CRS+HIPEC
Group B:CRS+HIPEC+Oral Drug

Sponsors

Shanghai Public Health Clinical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Primary or recurrent disease; 2. Histological confirmation of primary (or recurrent) and metastatic disease; 3. Aged between 20 to 75 years; 4. Patient Karnofsky performance scale (KPS) > 70 (normal activity with a bit of effort).

Exclusion criteria

Exclusion criteria: 1. Pregnancy; 2. Any metastatic disease outside the abdominal compartment, such as pulmonary or bone metastases; 3. Peritoneal carcinomatosis index (PCI) > 20 at the start of CRS.

Design outcomes

Primary

MeasureTime frame
overall survival;progression-free survival;—

Countries

China

Contacts

Public ContactLu Weiqi

Shanghai Public Health Clinical Center

yanghualab@yeah.net+86 13402101131

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026